Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Pharmaceutical Blockbuster Launches: Steal this Strategy
- CHAPEL HILL, N.C. -- Intense competition, looming patent expirations and the pressure to lower drug costs are compelling pharmaceutical companies to execute marketing earlier and with more focus than ever before. New research by pharmaceutical benchmarking leader, Best Practices, LLC, reveals how companies attain rapid market penetration and spectacular sales...
- Research articles 2004-09-30
- Pharmaceutical Blockbuster Launches: Steal This Strategy
- CHAPEL HILL, N.C. -- Intense competition, looming patent expirations and the pressure to lower drug costs are compelling pharmaceutical companies to execute marketing earlier and with more focus than ever before. New research by pharmaceutical benchmarking leader, Best Practices, LLC, reveals how companies attain rapid market penetration and spectacular sales...
- Research articles 2004-07-23
- Auriga Files Advanced Drug-Delivery Patent Application to Significantly Expand Revenues from Proprietary Drug Brands; Platform Technology Strengthens Company's Strategy to Extend Brand Exclusivity in Multibillion-Dollar Pharmaceutical Markets
- NORCROSS, Ga. -- Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company driving high-growth revenues through acquisition of valuable brand portfolios and innovative drug development programs, today announced the filing of a new provisional patent application for a key platform technology that will provide market exclusivity of its proven pharmaceutical brands.
- Research articles 2006-09-15
- DuPont Pharmaceuticals Highlights Growth Strategy at Socma Meeting.
- AMID THE ROAR of giant' drug companies dominating the pharmaceutical landscape, DuPont Pharmaceuticals Company, the wholly owned subsidiary of E. I. du Pont de Nemours & Co., is moving toward joining the top-ranking pharmaceutical firms by main AMID THE ROAR of giant' drug companies...
- Research articles 2000-03-27
- Robert Bazell, Chief Medical and Science Correspondent, NBC News, to Discuss Strategies for Enhancing Pharma's Image and Public Perception
- NEW YORK -- With the increased scrutiny on pharmaceutical companies due to drug recalls and safety alerts, the public image of the pharmaceutical industry has been tarnished. Robert Bazell, Chief Medical and Science Correspondent, NBC News, will discuss strategies for enhancing the industry's image and public perception through effective media...
- Research articles 2005-03-10
- Rhodia Strategically Positions Its Pharma Ingredients Business.(Brief Article)(Statistical Data Included)
- Rhodia is repositioning its pharmaceutical ingredients business as part of its strategy to expand its leading position in key markets. A major part of that strategy is to reinforce its status as a high-security, low-risk global supplier of pharmace Rhodia is repositioning its pharmaceutical...
- Research articles 2000-04-03
- European specialty players revamp and replace their strategy. (Focus 2003: Specialty Chemicals/ChemSpec Europe Preview).
- Threatened with commoditization, companies take drastic measures, not only cutting costs and divesting operations, but also seeking an entirely different, closer relationship with their customers. Under pressure from sluggish demand, difficult Threatened with commoditization, companies take drastic measures, ...
- Research articles 2003-04-28
- European drug strategy makes Forest stand out; Revenue triples in 5 years; does firm need to turn over leaf to stay green?(News)(Forest Laboratories Inc.)
- Byline: samantha marshall After five years of dizzying gains, Forest Laboratories Inc. has become one of the few stars in an industry better known for incremental growth. Propelled by its ability to rapidly develop European drugs for the U.S. m ...
- Research articles 2003-12-08
- Corporate Credibility: Healing the Faith
- Business risks have reached their highest level in several decades due to upheavals in the business environment. But the control-oriented risk management systems that served pharmaceuticals well in the past are no longer adequate. Risks are now streaming in from many new directions. There is no doubt that the woes...
- White papers 2003-08-12
- Beyond the Blockbuster : Finding the Next Profit zone in Pharmaceuticals Through Business Design Thinking
- The rapid growth of pharma companies in the 1990s was driven by a ‘blockbuster' model. This model is under pressure: Slowing scientific innovation and rising development costs combine with prescribers, payors and patients becoming tougher customers. But investor expectations remain high as much of the value of companies is still...
- White papers 2003-01-01
- Strategies For Pharmaceuticals Companies: The State As A Customer
- This article outlines a plan for pharmaceutical companies that work with state governments. Although the uniqueness of each state does not allow a cookie-cutter approach, companies can set goals and make use of frameworks that will help ensure future success with the state as a customer. States—and even the federal...
- White papers 2003-01-01
- Healthcare, Pharmaceutical And Biotech Resilient Amid Job Market Woes
- On the one hand where most industries were badly hit by the aftermath of September 11 incidents, there were few exceptions also. The industries such as healthcare, pharmaceutical, and biotech remained flexible despite job market's affliction. The paper elaborates on how the exceptional industries remained untouched by the suffering economy....
- White papers 2003-01-01
- Regulating The Outsource Provider
- From the executive summary: ‘Excellence is never cheap, because it stems from a sound approach, experience, and time-intensive work. The cost to a product development program for truly outstanding consultation is worth avoiding the risk of failed clinical trial, major regulatory errors or even the loss of a small amount...
- White papers 2003-01-01
- The Formula For Outsourcing Success
- Good project management at all levels of the organization results from effective communication and teamwork between the client and contractor. The appointment of an ombudsman by the client and the contractor culminates into an effective project management. Four factors are responsible for successful partnership between the client and the contractor....
- White papers 2003-01-01
- Outlook: Potential and Pitfalls in Pharmaceuticals
- There are potentially massive profits to be made in the pharmaceuticals' industry, if it can overcome the massive challenges posed by regulation, financing, and globalization, according to executives and venture capitalists. This has been outlined in this paper. It is also agreed that mapping the human genome has created great...
- White papers 2003-04-16
- People - The Key to Optimizing the Pipeline
- The challenges currently facing the pharmaceutical industry are myriad. Whether it is the failure to meet R & D productivity goals, the scarcity of talent, changing demographics and skills requirements, or the advance of individualized medicine, it will be people, the industry's primary asset, who will shape the response to...
- White papers 2003-09-24
- Industry Insight: New Environment
- Protecting intellectual property is paramount in the pharmaceutical industry. The new rules require that companies disclose their reasons for doing a deal and paying a premium over book value. Because this is sensitive data in a consolidating industry, companies and their advisers must develop best practices for complying with these...
- White papers
- Health Care Distribution and Service Companies: Reflections on a Changing Business Model
- The pharmaceutical distribution sector is undergoing a change in the very structure of its core business model, shifting from a traditional "buy-and-hold" model to a fee-for-service model that is more akin to just-in-time inventory. Under the current traditional business model, distributors, to varying degrees, make a portion of their margin...
- White papers 2004-05-05
- The Human and Economic Value of Pharmaceutical Innovation and Opportunities for the NHS
- Innovation is vital in the health care system. Innovation can be about improving compliance with existing treatment regimes, bringing new ways of treating patients, providing their treatment more cost effectively, or expanding the boundaries of what can be treated. Innovation can come in many forms new medicines, different devices, improved...
- White papers 2004-05-07
- Code of Practice for the Pharmaceutical Industry 2003
- The paper informs that investment into researching and developing new products in the UK is now running at around ·3.2 billion a year and each new medicine takes an average of ten to twelve years to develop before it is authorized for use by doctors, with no guarantee of commercial...
- White papers 2004-08-09
- << Previous
- page 1 of 4
- Next >>
Content Types
Refining Tags
- Management (49 results)
- Business Operations (10 results)
- Marketing (7 results)
- Innovation (6 results)
- Leadership (6 results)
- Research & Development (6 results)
- Biotechnology (5 results)
- Enterprise Software (5 results)
- Software (5 results)
- Finance (5 results)
- Health Care (5 results)
- Alliance (4 results)
- PricewaterhouseCoopers Consulting (4 results)
- Data Management (4 results)
- Sales (4 results)
- Accenture Ltd. (4 results)
- Vertical Industries (3 results)
- Human Resources (3 results)
- Marketing Research (3 results)
- Sales Force Management (3 results)
- Product Marketing (3 results)
- Manufacturing (3 results)
- Blockbuster Inc. (3 results)
- Capgemini (3 results)
